Editorial
Essential components of the maintenance phase of complex decongestive therapy
Medical oncology (Northwood, London, England), Vol.41(11), 289
10/17/2024
DOI: 10.1007/s12032-024-02442-1
PMID: 39417935
Abstract
Complex decongestive therapy is the current gold standard for non-surgical clinical lymphedema management and consists of manual therapy, compression exercise, skincare, and education. Complex decongestive therapy involves an intensive volume reduction phase (Phase I) followed by a maintenance phase (Phase II). The aim of the maintenance phase is to promote life-long control of lymphedema through use of self-management strategies and the provision of ongoing reduction therapies as needed. Compression therapies are the mainstay of lymphedema self-management. Poor adherence to self-management practices has been associated with increased volume and progression of lymphedema to more advanced stages, supporting the importance of education and regular monitoring to promote adherence to the Phase II maintenance recommendations. In this editorial, we provide consensus recommendations on the essential components of the maintenance phase, including education, skin care practices, managing infection/cellulitis, compression therapies, health and weight management, exercise, and ongoing follow-up care.
Details
- Title: Subtitle
- Essential components of the maintenance phase of complex decongestive therapy
- Creators
- Margaret L McNeely - University of AlbertaMona M Al Onazi - University of AlbertaMike Bond - University of Wisconsin–MadisonAndrea Brennan - Smith FamilyHeather Ferguson - Lymphedema Therapy (United States)Deborah A Gross - Lymphedema Association of North America, St Louis, MO, USAFedor Lurie - University of MichiganLinda Menzies - Menzies ProCare, Morden, MB, CanadaSteven Norton - Norton School of Lymphatic Therapy, Jameburg, NJ, USAYuanlu Sun - University of IowaAlaina Newell - Select Medical, Mechanicsburg, PA, USA
- Resource Type
- Editorial
- Publication Details
- Medical oncology (Northwood, London, England), Vol.41(11), 289
- DOI
- 10.1007/s12032-024-02442-1
- PMID
- 39417935
- NLM abbreviation
- Med Oncol
- ISSN
- 1357-0560
- eISSN
- 1559-131X
- Publisher
- HUMANA PRESS INC
- Grant note
This expert consensus is a product of a workshop from the 2023 Lymphedema Summit: Forward Momentum; Future Steps in Lymphedema Management. This Summit was sponsored by the American Cancer Society, the Lymphology Association of North America, Washington University School of Medicine in St. Louis, and the Stryker Corporation.
- Language
- English
- Date published
- 10/17/2024
- Academic Unit
- Nursing
- Record Identifier
- 9984736599002771
Metrics
11 Record Views